Clinicopathological data of paired diagnosis and recurrence cHL cohort at the time of primary diagnosis
| Total cohort (N = 60) . | n (%) . |
|---|---|
| Sex (N = 60) | |
| Male | 37 (62) |
| Female | 23 (38) |
| Median age (N = 60) | 26 y (4-76 y) |
| Pediatric (≤18 y) | 18 (30) |
| Adults (>18 y) | 42 (70) |
| Disease stage Ann Arbor (n = 52) | |
| I | 6 (12) |
| II | 19 (37) |
| III | 17 (33) |
| IV | 10 (19) |
| Risk groups (n = 40) | |
| Stages I to II (n = 24) | |
| EORTC favorable | 9 (23) |
| EORTC unfavorable | 15 (38) |
| Stages III to IV (n = 16) | |
| IPS 0 to 2 | 8 (20) |
| IPS ≥3 | 8 (20) |
| First line treatment (n = 52)∗ | |
| Chemotherapy | 49 (94) |
| Radiotherapy | 20 (38) |
| Immunotherapy | 1 (2) |
| Time to first recurrence (N=60) | |
| Median interval (range) (y) | 1.5 (0.4-13.6) |
| cHL subtype (N = 60) | |
| NSHL | 34 (57) |
| MCHL | 22 (37) |
| LRHL | 1 (2) |
| cHL-NOS | 3 (5) |
| EBV status (N = 60) | |
| Negative | 47 (78) |
| Positive | 13 (22) |
| Total cohort (N = 60) . | n (%) . |
|---|---|
| Sex (N = 60) | |
| Male | 37 (62) |
| Female | 23 (38) |
| Median age (N = 60) | 26 y (4-76 y) |
| Pediatric (≤18 y) | 18 (30) |
| Adults (>18 y) | 42 (70) |
| Disease stage Ann Arbor (n = 52) | |
| I | 6 (12) |
| II | 19 (37) |
| III | 17 (33) |
| IV | 10 (19) |
| Risk groups (n = 40) | |
| Stages I to II (n = 24) | |
| EORTC favorable | 9 (23) |
| EORTC unfavorable | 15 (38) |
| Stages III to IV (n = 16) | |
| IPS 0 to 2 | 8 (20) |
| IPS ≥3 | 8 (20) |
| First line treatment (n = 52)∗ | |
| Chemotherapy | 49 (94) |
| Radiotherapy | 20 (38) |
| Immunotherapy | 1 (2) |
| Time to first recurrence (N=60) | |
| Median interval (range) (y) | 1.5 (0.4-13.6) |
| cHL subtype (N = 60) | |
| NSHL | 34 (57) |
| MCHL | 22 (37) |
| LRHL | 1 (2) |
| cHL-NOS | 3 (5) |
| EBV status (N = 60) | |
| Negative | 47 (78) |
| Positive | 13 (22) |
EORTC, European Organization of Research and Treatment of Cancer; IPS, international prognostic score; LRHL, lymphocyte rich Hodgkin lymphoma; NOS, not otherwise specified.
If patients received combination therapy, multiple treatment categories were applicable, making the sum of all categories >100%. For detailed information, see supplemental Table 1.